- Investing Ideas
- Hong Kong Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Hong Kong Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Results
6
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
6 companies
CanSino Biologics
Market Cap: HK$10.3b
Develops, manufactures, and commercializes vaccines in the People’s Republic of China.
6185
HK$24.50
7D
6.8%
1Y
-35.5%
Sichuan Kelun-Biotech Biopharmaceutical
Market Cap: HK$128.2b
A biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs in oncology, immunology, metabolism, and other therapeutic areas in the People’s Republic of China and internationally.
6990
HK$536.50
7D
11.9%
1Y
51.0%
Akeso
Market Cap: HK$95.3b
A biopharmaceutical company, engages in the research, development, manufacture, and commercialization of antibody drugs worldwide.
9926
HK$103.50
7D
7.3%
1Y
-17.9%
Innovent Biologics
Market Cap: HK$169.0b
A biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People’s Republic of China, the United States, Europe, and internationally.
1801
HK$97.05
7D
12.6%
1Y
12.6%
Biocytogen Pharmaceuticals (Beijing)
Market Cap: HK$57.8b
A biotechnology company, engages in the research and development of novel antibody-based drugs and pre-clinical research services in the People’s Republic of China, the United States, and internationally.
2315
HK$58.85
7D
26.3%
1Y
175.6%
WuXi XDC Cayman
Market Cap: HK$79.1b
An investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally.
2268
HK$62.65
7D
7.5%
1Y
28.4%